Anna Sureda, MD, PhD | Authors


A Study of Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma

February 01, 2018

Anna Sureda, MD, PhD, Head of the Clinical Hematology Service at the Institut Català d'Oncologia – Hospitalet de Llobregat in Barcelona, discusses the phase III ECHELON-1 study exploring brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma.